Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma.
Cawood
T J
TJ
Bridgman
P
P
Hunter
L
L
Cole
D
D
D002545:Brain Ischemia / Q000150:complications; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D005355:Fibrosis; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D007415:Intestinal Obstruction / Q000150:complications; D008297:Male; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000139:chemically induced* / Q000150:complications / Q000473:pathology / Q000601:surgery; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D015175:Prolactinoma / Q000188:drug therapy*; D014262:Tricuspid Valve Insufficiency / Q000139:chemically induced* / Q000150:complications / Q000473:pathology / Q000601:surgery; D018487:Ventricular Dysfunction, Left / Q000209:etiology
D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline